Crohn's, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, Crohn's

Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E 1987 Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22: 655-664.
Aamodt G, Bukholm G, Jahnsen J, Moum B, Vatn MH; the IBSEN Study Group 2008 The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in Southeastern Norway. Am. J. Epidemiol. Sep 18 [Epub ahead of print]. *
Aamodt G, Jahnsen J, Bengtson MB, Moum B, Vatn MH; the IBSEN Study Group 2008 Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993. Inflamm. Bowel Dis. 14: 984-991.
Aase S, Koppang HS, Solheim T, Kjaerheim A, Axell T, Storhaug K, Refsum S 2001 Crohn disease of the oral cavity, illustrated by some cases. Tidsskr. Nor. Laegeforen. 121: 2489-2491.
Abad C, Gomariz RP, Waschek JA 2006 Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr. Top. Med. Chem. 6: 151-163.
Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gomez M, Leceta J, Gomariz RP 2005 cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 11: 674-684. *
Abad E, Tural C, Mirapeix E, Cuxart A 1997 Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J. Autoimmun. 10: 175-180. *
Abadia-Molina AC, Ji H, Faubion WA, Julien A, Latchman Y, Yagita H, Sharpe A, Bhan AK, Terhorst C 2006 CD48 controls T cell and antigen-presenting cell functions in experimental colitis. Gastroenterology 130: 424-434. *
Abakar-Mahamat A, Filippi J, Pradier C, Dozol A, Hebuterne X 2007 Incidence of inflammatory bowel disease in Corsica from 2002 to 2003. Gastroenterol. Clin. Biol. 31: 1098-1103.
Abbas Z, Khan R, Abid S, Hamid S, Shah H, Jafri W 2004 Is Crohn's disease in Pakistan less severe than in the West? Trop. Doct. 34: 39-41.
Abbott DW, Wilkins A, Asara JM, Cantley LC 2004 The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14: 2217-2227. *
Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC 2007 Coordinate regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol. Cell. Biol. 27: 6012-6025. *
Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF 2007 Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunis. Med. 85: 569-572.
Abdelmalek MF, Liu C, Valentine JF 2007 Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am. J. Gastroenterol. 102: 1333-1334.
Abdul-Baki H, Elhajj I, El-Zahabi LM, Azar C, Aoun E, Zantout H, Nasreddine W, Ayyach B, Mourad FH, Soweid A, Barada KA, Sharara AI 2007 Clinical epidemiology of inflammatory bowel disease in Lebanon. Inflamm. Bowel Dis. 13: 475-480. *
Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda SI, Tsutsumi Y 2008 Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J. Immunol. Methods 335: 71-78. *
Abedin M, Scheurich D, Reimold SC, Reimold AM 2006 Acute coronary syndrome after infliximab infusion. Cardiol. Rev. 14: 50-52.
Aberra FN 2008 Omega-3 fatty acids for maintenance of remission of Crohn's disease. Gastroenterology 135: 1005-1006. *
Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD 2005 Antibiotic use and the risk of flare of inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 3: 459-465. *
Aberra FN, Lichtenstein GR 2005 Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment. Pharmacol. Ther. 21: 307-319. *
Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD 2007 Risk for active tuberculosis in inflammatory bowel disease patients. Clin. Gastroenterol. Hepatol. 5: 1070-1075.
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B 1995 Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108: 417-422. *
Ablassmaier B, Hartmann J 2004 A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake. Zentralbl. Chir. 129: 510-512.
Abo T, Kawamura T, Kawamura H, Tomiyama-Miyaji C, Kanda Y 2007 Relationship between diseases accompanied by tissue destruction and granulocytes with surface adrenergic receptors. Immunol. Res. 37: 201-210.
Abraham C, Cho JH 2006 Functional consequences of NOD2 (CARD15) mutations. Inflamm. Bowel Dis. 12: 641-650. *
Abreu MT 2006 Serologies in Crohn's disease: can we change the gray zone to black and white? Gastroenterology 131: 664-667. *
Abreu MT 2005 Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 210-211. *
Abreu MT 2007 Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev. Gastroenterol. Disord. 7 Suppl. 1: S20-S26.
Abreu MT 2007 Certolizumab pegol in Crohn's disease: a viewpoint by Maria T. Abreu. BioDrugs 21: 202-203.
Abreu MT 2004 Choosing therapy on the basis of disease classifications in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 7: 169-179.
Abreu MT 2002 The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol. Rep. 4: 481-489.
Abreu MT 2003 Immunologic regulation of Toll-like receptors in gut epithelium. Curr. Opin. Gastroenterol. 19: 559-564.
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR 2006 Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J. Clin. Gastroenterol. 40: 55-63.
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin YC, Yang H, Hewison M, Adams JS 2004 Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53: 1129-1136. *
Abreu MT, Plevy S, Sands BE, Weinstein R 2007 Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 874-888.
Abreu MT, Sparrow MP 2006 Translational research in inflammatory bowel disease. Mt. Sinai J. Med. 73: 1067-1073. *
Abreu MT, Sparrow MP 2007 The role of translational research in inflammatory bowel disease. Rev. Gastroenterol. Mex. 72: 146-153.
Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H 2002 Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123: 679-688. *
Abreu MT, Yang H 2004 Is genetic testing in IBD ready for prime time? Am. J. Gastroenterol. 99: 316-318. *
Abu-Suboh Abadia M, Casellas F, Vilaseca J, Malagelada J 2004 Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev. Esp. Enferm. Dig. 96: 539-547.
Abubakar I, Myhill D, Aliyu SH, Hunter PR 2008 Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm. Bowel Dis. 14: 401-410. *
Abubakar I, Myhill DJ, Hart AR, Lake IR, Harvey I, Rhodes JM, Robinson R, Lobo AJ, Probert CS, Hunter PR 2007 A case-control study of drinking water and dairy products in Crohn's disease - further investigation of the possible role of Mycobacterium avium paratuberculosis. Am. J. Epidemiol. 165: 776-783. *
Abuzakouk M, Feighery C, Jackson J 2002 Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br. J. Biomed. Sci. 59: 173-179.
Acciuffi S, Ghosh S, Ferguson A 1996 Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment. Pharmacol. Ther. 10: 321-326. *
Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, et al 2006 Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am. J. Gastroenterol. 101: 572-580. *
Achkar JP, Duerr R 2008 The expanding universe of inflammatory bowel disease genetics. Curr. Opin. Gastroenterol. 24: 429-434. *
Achneck HE, Pradhan SK, Kavic SM, Longo WE 2005 Primary signet-ring cell carcinoma mimicking segmental Crohn's colitis. Dig. Liver Dis. 37: 537-541.
Achneck HE, Wong IY, Kim PJ, Fernandes MA, Walther Z, Seymour NE, Jain D 2005 Ileostomy adenocarcinomas in the setting of ulcerative colitis. J. Clin. Gastroenterol. 39: 396-400.
Achord JL, Gunn CH Jr, Jackson JF 1982 Regional enteritis and HLA concordance in multiple siblings. Dig. Dis. Sci. 27: 330-332.
Ackermann C, Kavanaugh A 2007 Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets 11: 1369-1384.
Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M 2008 Use of corticosteroids, immunomodulators, and Infliximab at a third-level day-hospital service of gastro-hepatology. Minerva Gastroenterol. Dietol. 54: 239-242.
Adachi JD, Rostom A 1999 Metabolic bone disease in adults with inflammatory bowel disease. Inflamm. Bowel Dis. 5: 200-211.
Adachi Y, Yoshio-Hoshino N, Nishimoto N 2008 The blockade of IL-6 signaling in rational drug design. Curr. Pharm. Des. 14: 1217-1224.
Adam SJ, Counter CM 2008 A method to generate genetically defined tumors in pigs. Methods Enzymol. 439: 39-51.
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS 2004 Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J. Am. Acad. Dermatol. 51: 660-662.
Adams RJ, Heazlewood SP, Gilshenan KS, O'Brien M, McGuckin MA, Florin TH 2008 IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am. J. Gastroenterol. 103: 386-396. *
Adamska I, Czerwionka-Szaflarska M, Kulwas A, Mierzwa G, Bala G, Rosc D 2007 Value of E-selectin and L-selectin determination in children and youth with inflammatory bowel disease. Med. Wieku. Rozwoj. 11: 413-418.
Adani GL, Baccarani U, Risaliti A, Donini A, Aoki T, Avital I 2003 Appendicectomy and Crohn's disease: clinical and genetic associations. Gastroenterology 125: 1562-1563. *
Addo A, Le J, Li W, Aksentijevich I, Balow J Jr, Lee A, Gregersen PK, Kastner DL, Remmers EF 2005 Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility. Scand. J. Rheumatol. 34: 198-203. *
Addolorato G, Capristo E, Stefanini GF, Gasbarrini G 1997 Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand. J. Gastroenterol. 32: 1013-1021.
Adibi SA 2003 Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G779-G788. *
Adler J, Raju S, Beveridge AS, Wang S, Zhu J, Zimmermann EM 2008 College adjustment in University of Michigan students with Crohn's and colitis. Inflamm. Bowel Dis. 14: 1281-1286.
Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP 1991 Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig. Dis. Sci. 36: 449-453.
Afzal MA, Armitage E, Ghosh S, Williams LC, Minor PD 2000 Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. J. Med. Virol. 62: 377-382. *
Afzal MA, Minor PD, Armitage E, Ghosh S 1999 Measles virus and Crohn's disease. Gut 44: 896-897. *
Afzal MA, Minor PD, Schild GC 2000 Clinical safety issues of measles, mumps and rubella vaccines. Bull. World Health Organ. 78: 199-204.
Afzal NA, Davies S, Paintin M, Arnaud-Battandier F, Walker-Smith JA, Murch S, Heuschkel R, Fell J 2005 Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci. 50: 1471-1475. *
Afzal NA, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R 2007 Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig. Dis. Sci. 52: 3329-3333. *
Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Davies S, Murch S, Derkx B, Heuschkel R, Fell JM 2004 Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment. Pharmacol. Ther. 20: 167-172. *
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF 2004 Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 5: 289-293. *
Agapov M 2006 Balantidiasis in a patient with suspected Crohn's disease. Endoscopy 38: 655. *
Aggarwal BB, Shishodia S 2004 Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441.
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H 2006 TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186.
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F 2005 Inflammatory bowel disease in Iran: a review of 457 cases. J. Gastroenterol. Hepatol. 20: 1691-1695. *
Aghdassi E, Wendland BE, Stapleton M, Raman M, Allard JP 2007 Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. J. Am. Diet. Assoc. 107: 1575-1580.
Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP 2003 Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. Am. J. Gastroenterol. 98: 348-353. *
Agius LM 2004 A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis. J. Theor. Biol. 227: 219-228. *
Agnholt J 2008 Biological therapy as treatment of inflammatory bowel diseases. Ugeskr. Laeger. 170: 2152-2156.
Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E 2003 Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment. Pharmacol. Ther. 17: 703-710. *
Agnholt J, Dahlerup JF, Kaltoft K 2003 The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85. *
Agnholt J, Kaltoft K, Jakobsen NO, Dahlerup JF 2002 T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. Cytokines Cell Mol. Ther. 7: 117-123.
Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF 2004 Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol. 16: 649-655.
Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES 2007 Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease. Scand. J. Immunol. 65: 453-460. *
Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM 2005 Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 1215-1220.
Agrawal D, Rukkannagari S, Kethu S 2007 Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol. 53: 233-248.
Agret F, Cosnes J, Hassani Z, Gornet JM, Gendre JP, Lemann M, Beaugerie L 2005 Impact of pregnancy on the clinical activity of Crohn's disease. Aliment. Pharmacol. Ther. 21: 509-513. *
Aguas M, Bastida G, Nos P, Beltran B, Grueso JL, Ponce J 2007 Septic thrombophlebitis of the superior mesenteric vein and multiple liver abscesses in a patient with Crohn's disease at onset. BMC Gastroenterol. 7: 22. *
Aguilera-Montilla N, Perez-Blas M, Valeri AP, Lopez-Santalla M, Rodriguez-Juan C, Mencia A, Castellano G, Manzano ML, Casis B, Sanchez F, Martin-Villa JM 2004 Higher proliferative capacity of T lymphocytes from patients with Crohn disease than from ulcerative colitis is disclosed by use of Herpesvirus saimiri-transformed T-cell lines. Scand. J. Gastroenterol. 39: 1236-1242. *
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M 2003 New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453.
Aharoni R, Kayhan B, Arnon R 2005 Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm. Bowel Dis. 11: 106-115. *
Ahmad K, Rogers S 2007 Development of Crohn disease in a patient on etanercept for psoriasis. Br. J. Dermatol. 157: 396.
Ahmad NM, Ahmad KM, Younus F 2007 Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease. J. Infect. 54: e29-e32.
Ahmad S, Tester RF, Corbett A, Karkalas J 2006 Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr. Res. 341: 2694-2701. *
Ahmad T 2004 Phenotype-determining genes in inflammatory bowel disease. Novartis Found. Symp. 263: 17-29.
Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP 2002 The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122: 854-866. *
Ahmad T, Marshall S, Jewell D 2003 Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 19: 327-335.
Ahmad T, Marshall SE, Jewell D 2006 Genetics of inflammatory bowel disease: the role of the HLA complex. World J. Gastroenterol. 12: 3628-3635. *
Ahmad T, Marshall SE, Mulcahy-Hawes K, Orchard T, Crawshaw J, Armuzzi A, Neville M, van Heel D, Barnardo M, Welsh KI, Jewell DP, Bunce M 2002 High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibility. Tissue Antigens 60: 164-179. *
Ahmad T, Pesi Tamboli C, Jewell D, Colombel JF 2004 Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126: 1533-1549. *
Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP 2001 Review article: the genetics of inflammatory bowel disease. Aliment. Pharmacol. Ther. 15: 731-748. *
Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, Fayyad F, James T, Neville M, Kanawati C, Fortune F, Celik A, Stanford M, Jewell DP, Marshall SE 2005 CARD15 polymorphisms in Behcet's disease. Scand. J. Rheumatol. 34: 233-237.
Ahmadi AA, Polyak S 2007 Endoscopy/surveillance in inflammatory bowel disease. Surg. Clin. North Am. 87: 743-762.
Ahman T 2004 Molecular classification of IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 27. May 7-8. *
Ahmed FE 2006 Role of genes, the environment and their interactions in the etiology of inflammatory bowel diseases. Expert Rev. Mol. Diagn. 6: 345-363.
Ahmed I, Boulter MK, Lobo DN 2006 The SLAPPA (significance of lower abdominal/periumbilical piercing as a predictor of acute appendicitis) audit. Sex Health 3: 195-196.
Ahmed KA, Thompson JW, Joyner RE, Stocks RM 2005 Airway obstruction secondary to tracheobronchial involvement of asymptomatic undiagnosed Crohn's disease in a pediatric patient. Int. J. Pediatr. Otorhinolaryngol. 69: 1003-1005.
Ahmed M, Jenkins HR 2004 Vitamin B-12 in Crohn's disease patients with small bowel surgery. Arch. Dis. Child. 89: 293. *
Ahmed M, Kosgallana A, Soon D, O'Donovan D, Chaudhuri A 2008 Respiratory muscle weakness in a patient with quiescent Crohn's disease and pneumonia. QJM 101: 245-247.
Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGrogan P, Weaver LT 2004 Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J. Pediatr. Gastroenterol. Nutr. 38: 276-280. *
Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R 2006 Risk of postoperative infection in patients with inflammatory bowel disease. Korean J. Gastroenterol. 48: 306-312.
Ahn LB, Huang CS, Forse RA, Hess DT, Andrews C, Farraye FA 2005 Crohn's disease after gastric bypass surgery for morbid obesity: is there an association? Inflamm. Bowel Dis. 11: 622-624. *
Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ, Inoue Y 2008 Hepatocyte nuclear factor 4 in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm. Bowel Dis. 14: 908-920.
Ahuja V 2004 Crohn's disease and mycobacteria: 'the Thomson brothers' or 'back to the future'. Trop. Gastroenterol. 25: 151-155.
Aihara H, Hiwatashi N 1999 Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis. Nippon Rinsho 57: 2476-2480.
Ainsworth MA, Bendtzen K, Brynskov J 2008 Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am. J. Gastroenterol. 103: 944-948. *
Ainsworth MA, Brynskov J 2007 Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis. Ugeskr. Laeger. 169: 789-791.
Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RAF, Yager J, Bodian C, Gorfine SR, Bauer JJ, Plevy SE, Sachar DB 2004 Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am. J. Gastroenterol. 99: 432-441. *
Aisenberg J, Wagreich J, Shim J, Almer S, Peen E, Heimann T, Gelernt IM, Greenstein A, Rubin P, Harpaz N, et al 1995 Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Dig. Dis. Sci. 40: 1866-1872.
Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, Hudson M 2001 Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Dig. Dis. Sci. 46: 1520-1525. *
Aithal GP, Day CP, Leathart J, Daly AK, Hudson M 2001 Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immun. 2: 44-47. *
Aizawa Y, Sutoh S, Matsuoka M, Negishi M, Torii A, Miyakawa Y, Sugisaka H, Nakamura M, Toda G 2005 Association of interleukin-18 gene single-nucleotide polymorphisms with susceptibility to inflammatory bowel disease. Tissue Antigens 65: 88-92. *
Ajaj W, Goyen M, Langhorst J, Ruehm SG, Gerken G, Lauenstein TC 2006 MR colonography for the assessment of colonic anastomoses. J. Magn. Reson. Imaging 24: 101-107.
Ajaj W, Lauenstein TC, Langhorst J, Kuehle C, Goyen M, Zoepf T, Ruehm SG, Gerken G, Debatin JF, Goehde SC 2005 Small bowel hydro-MR imaging for optimized ileocecal distension in Crohn's disease: should an additional rectal enema filling be performed? J. Magn. Reson. Imaging 22: 92-100.
Ajlouni Y, Iser JH, Gibson PR 2007 Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. J. Gastroenterol. Hepatol. 22: 486-490. *
Akagi S, Hiyama E, Imamura Y, Takesue Y, Matsuura Y, Yokoyama T 2000 Interleukin-10 expression in intestine of Crohn disease. Int. J. Mol. Med. 5: 389-395.
Akahoshi M, Ishihara M, Namba K, Kitaichi N, Ando Y, Takenaka S, Ishida T, Ohno S, Mizuki N, Nakashima H, Shirakawa T 2008 Mutation screening of the CARD15 gene in sarcoidosis. Tissue Antigens 71: 564-567. *
Akay N, Boyvat A, Heper AO, Soykan I, Arica IE, Bektas M, Ensari A, Cokca F 2006 Behcet's disease-like presentation of bullous pyoderma gangrenosum associated with Crohn's disease. Clin. Exp. Dermatol. 31: 384-386. *
Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K, Okita K 2002 Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J. Gastroenterol. 37: 345-353. *
Akbayir N, Calis AB, Alkim C, Sokmen HM, Erdem L, Ozbal A, Bolukbas F, Akbayir N 2005 Sensorineural hearing loss in patients with inflammatory bowel disease: a subclinical extraintestinal manifestation. Dig. Dis. Sci. 50: 1938-1945. *
Akbulut S, Yavuz B, Koseoglu T, Gokoz A, Saritas U 2004 Crohn's disease with isolated esophagus and gastric involvement. Turk. J. Gastroenterol. 15: 196-200. *
Akcam M, Artan R, Yilmaz A, Cig H, Aksoy NH 2005 Abdominal tuberculosis in adolescents. Difficulties in diagnosis. Saudi Med. J. 26: 122-126.
Akhavan A, Jackman SV, Costa G, Davies B, Wu T, Bond G, Abu-Elmagd K 2007 Urogenital disorders associated with gut failure and intestinal transplantation. J. Urol. 178: 2067-2072.
Akiho H, Lovato P, Deng Y, Ceponis PJ, Blennerhassett P, Collins SM 2005 Interleukin-4 and -13-induced hypercontractility of human intestinal muscle cells: implication for motility changes in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G609-G615. *
Akman SA, Arikan C, Sozen G, Ozturk C, Yagci RV 2006 Infliximab treatment of pediatric refractory Crohn's disease: a case report. Turk. J. Gastroenterol. 17: 133-136. *
Akobeng A, Thomas A 2007 Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD005984. *
Akobeng A, Zachos M 2004 Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD003574. *
Akobeng AK 2008 Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment. Pharmacol. Ther. 27: 11-18. *
Akobeng AK 2008 Anti-mycobacterials and Crohn's disease: author's reply. Aliment. Pharmacol. Ther. 28: 374-375. *
Akobeng AK 2008 Crohn's disease: current treatment options. Arch. Dis. Child. 93: 787-792.
Akobeng AK, Gardener E 2004 Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease Cochrane Database Syst. Rev. 1: CD003715. *
Akobeng AK, Richmond K, Miller V, Thomas AG 2007 Effect of exclusive enteral nutritional treatment on plasma antioxidant concentrations in childhood Crohn's disease. Clin. Nutr. 26: 51-56.
Akolkar PN, Gulwani-Akolkar B, Heresbach D, Lin XY, Fisher S, Katz S, Silver J 1997 Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. Am. J. Gastroenterol. 92: 2241-224.
Akolkar PN, Gulwani-Akolkar B, Lin XY, Zhou Z, Daly M, Katz S, Levine J, Present D, Gelb B, Desnick R, Mayer L, Silver J 2001 The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease. Am. J. Gastroenterol. 96: 1127-1132. *
Al-Ghamdi AS, Al-Mofleh IA, Al-Rashed RS, Al-Amri SM, Aljebreen AM, Isnani AC, El-Badawi R 2004 Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. World J. Gastroenterol. 10: 1341-1344. *
Al-Haddad S, Riddell RH 2005 The role of eosinophils in inflammatory bowel disease. Gut 54: 1674-1675. *
Al-Jarallah A, Oriowo MA, Khan I 2007 Mechanism of reduced colonic contractility in experimental colitis: role of sarcoplasmic reticulum pump isoform-2. Mol. Cell. Biochem. 298: 169-178. *
Al-Ratrout JT, Ansari NA 2004 Epidermolysis bullosa acquisita and Crohn's disease. Saudi Med. J. 25: 1736-1738.
Al-Sadi R, Ye D, Dokladny K, Ma TY 2008 Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J. Immunol. 180: 5653-5661.
Al-Shamali M, Khan I, Al-Nakib B, Al-Hassan F, Mustafa AS 1997 A multiplex polymerase chain reaction assay for the detection of Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Scand. J. Gastroenterol. 32: 819-823.
Al-Toma A, Mulder CJ 2007 Review article: stem cell transplantation for the treatment of gastrointestinal diseases - current applications and future perspectives. Aliment. Pharmacol. Ther. 26 Suppl. 2: 77-89. *
Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC 2005 Eruptive tufted angiomas in a patient with Crohn's disease. J. Clin. Pathol. 58: 214-216. *
Alam I, Nolan N, Geoghegan J 2004 Isolated Crohn's disease of the appendix. Ir. J. Med. Sci. 173: 114.
Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V 2004 New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr. Pharm. Des. 10: 3505-3524.
Albert JG, Kotsch J, Kostler W, Behl S, Kaltz B, Bokemeyer B, Dollinger MM, Haerting J, Fleig WE 2008 Course of Crohn's disease prior to establishment of the diagnosis. Z. Gastroenterol. 46: 187-192.
Albert JG, Martiny F, Krummenerl A, Stock K, Lesske J, Gobel CM, Lotterer E, Nietsch HH, Behrmann C, Fleig WE 2005 Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 54: 1721-1727. *
Albert JG, Wiedbrauck F, Keuchel M 2008 Small bowel endoscopy. Dtsch. Med. Wochenschr. 133: 1136-1141.
Albrecht K, Schumann R, Peitgen K, Walz MK 2004 Laparoscopic therapy of appendicovesical fistula - two case reports. Zentralbl. Chir. 129: 396-398.
Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR 2004 Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm. Bowel Dis. 10: 383-391. *
Aldebert D, Masy E, Reumaux D, Lion G, Colombel JF, Duthilleul P 1997 Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease. Dig. Dis. Sci. 42: 2350-2355. *
Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J 2007 Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am. J. Gastroenterol. 102: 577-588. *
Aldhous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J 2008 Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease? Inflamm. Bowel Dis. Jul 10 [Epub ahead of print]. *
Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H 2005 Saliva interleukin-6 in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1444-1448. *
Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P 2004 Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut 53: 85-90. *
Alexander F 2007 Complications of ileal pouch anal anastomosis. Semin. Pediatr. Surg. 16: 200-204.
Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR 2001 Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158: 527-535. *
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF 1996 Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease. Dig. Dis. Sci. 41: 660-669.
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF 1995 Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. Dig. Dis. Sci. 40: 485-494.
Alexis AF, Strober BE 2005 Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9: 296-302.
Alfadhli A, McDonald J, Feagan B 2005 Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459. *
Alfadhli AA, McDonald JW, Feagan BG 2003 Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459. *
Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, Aaltonen LA 2004 NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 64: 7245-7247. *
Alic M 2000 Crohn's disease epidemiology at the turn of the century-solving the puzzle. Am. J. Gastroenterol. 95: 321-323. *
Alic M 1999 Is exposure to a patient with Crohn's disease an environmental factor for developing the disease. Gut 45: 631-632. *
Alison M, Kheniche A, Azoulay R, Roche S, Sebag G, Belarbi N 2007 Ultrasonography of Crohn disease in children. Pediatr. Radiol. 37: 1071-1082.
Alkim C, Balci M, Alkim H, Dagli U, Parlak E, Tezel A, Ulker A 2007 The importance of peripheral immune cells in inflammatory bowel disease. Turk. J. Gastroenterol. 18: 82-88. *
Allen AS, Satten GA 2007 Statistical models for haplotype sharing in case-parent trio data. Hum. Hered. 64: 35-44.
Allen CA, Niesel DW, Torres AG 2008 The effects of low-shear stress on adherent-invasive Escherichia coli. Environ. Microbiol. 10: 1512-1525.
Allez M, Modigliani R 2000 Clinical features of inflammatory bowel disease. Curr. Opin. Gastroenterol. 16: 329-336.
Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lemann M, Mayer L, Toubert A 2007 CD4(+)NKG2D(+) T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132: 2346-2358. *
Allgayer H 1992 Sulfasalazine and 5-ASA compounds. Gastroenterol. Clin. North Am. 21: 643-658.
Allgayer H, Holtmeier W, Dietrich CF 2007 Crohn's disease and cancer risk. Incidence/prevalence, clinical characteristics, and potential prevention strategies. Med. Klin. (Munich) 102: 727-733.
Allgayer H, Kruis W 1990 Recent knowledge of the pathophysiology of inflammation in Crohn disease and ulcerative colitis: possible sequelae for future treatment concepts. Z. Gastroenterol. 28: 117-120.
Allgayer H, Roisch U, Zehnter E, Ziegenhagen DJ, Dienes HP, Kruis W 2007 Colonic ornithine decarboxylase in inflammatory bowel disease: ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features. Dig. Dis. Sci. 52: 25-30. *
Allison MC, Poulter LW 1991 Changes in phenotypically distinct mucosal macrophage populations may be a prerequisite for the development of inflammatory bowel disease. Clin. Exp. Immunol. 85: 504-509. *
Allison SP, Williams L, Sandhar B, Swaffield G, Newman GH, Bastow MD, Fox JE, Hardcastle JH 1983 Supplementation of nutritional fluid and electrolyte balance by perfusion of an isolated small bowel loop in a patient with Crohn's disease. Clin. Nutr. 2: 107-111.
Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF 2005 ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54: 565. *
Alluwaimi AM 2007 The etiology of Mycobacterium avium subspecies paratuberculosis in Crohn's disease. Saudi Med. J. 28: 1479-1484.
Ally MR, Veerappan GR, Koff JM 2008 Treatment of recurrent Crohn's uveitis with infliximab. Am. J. Gastroenterol. Jun 16 [Epub ahead of print]. *
Almeida N, Portela F, Oliveira P, Duarte A, Gregorio C, Gomes D, Gouveia H, Leitao MC 2008 Meningitis in a patient with previously undiagnosed Crohn's disease. Inflamm. Bowel Dis. Aug 4 [Epub ahead of print].
Almer S, Granerus G, Strom M, Olaison G, Bonnet J, Lemann M, Smedh K, Franzen L, Bertheau P, Cattan P, Rain JD, Modigliani R 2007 Leukocyte scintigraphy compared to intraoperative small bowel enteroscopy and laparotomy findings in Crohn's disease. Inflamm. Bowel Dis. 13: 164-174. *
Almer SH, Hjortswang H, Hindorf U 2008 6-Thioguanine therapy in Crohn's disease - observational data in Swedish patients. Dig. Liver Dis. Sep 15 [Epub ahead of print].
Alos R, Hinojosa J 2008 Timing of surgery in Crohn's disease: a key issue in the management. World J. Gastroenterol. 14: 5532-5539. *
Alpers DH 2002 The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr. Opin. Gastroenterol. 18: 203-208.
Alqahtani S, Coffin CS, Burak K, Chen F, Macgregor J, Beck P 2007 Hepatic portal venous gas: a report of two cases and a review of the epidemiology, pathogenesis, diagnosis and approach to management. Can. J. Gastroenterol. 21: 309-313.
Alrefai WA, Saksena S, Tyagi S, Gill RK, Ramaswamy K, Dudeja PK 2007 Taurodeoxycholate modulates apical Cl(-)/OH(-) exchange activity in Caco2 cells. Dig. Dis. Sci. 52: 1270-1278. *
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D 2007 Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J. Clin. Periodontol. 34: 610-617.
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D 2008 Impact of local and systemic factors on the incidence of late oral implant loss. Clin. Oral Implants Res. 19: 670-676.
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D 2008 Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57.
Alstead EM 2002 Inflammatory bowel disease in pregnancy. Postgrad. Med. J. 78: 23-26. *
Altarescu G, Elstein D 2005 Coexistence of Fabry disease and Crohn's disease: a case report. Inflamm. Bowel Dis. 11: 87-88. *
Altschuler EL 2000 Mycophenolate mofetil, Crohn's disease, measles? Am. J. Gastroenterol. 95: 550-551. *
Altschuler EL, Kast RE 2004 Bupropion for Blau syndrome. Med. Hypotheses 62: 297-298.
Alvarez-Blanco M, Fernandez-Mere LA, Martinez-Rodriguez E 2005 Crohns disease of the appendix. Cir. Esp. 78: 333-335.
Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Piu J, Reverter JC, Pique JM, Yague J, Panes J 2007 Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn's disease behaviour. Aliment. Pharmacol. Ther. 25: 429-440. *
Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yague J, Panes J 2005 Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg. 242: 693-700. *
Alves A, Panis Y, Bouhnik Y, Marceau C, Rouach Y, Lavergne-Slove A, Vicaut E, Valleur P 2005 Factors that predict conversion in 69 consecutive patients undergoing laparoscopic ileocecal resection for Crohn's disease: a prospective study. Dis. Colon Rectum 48: 2302-2308. *
Alves A, Panis Y, Joly F, Pocard M, Lavergne-Slove A, Bouhnik Y, Valleur P 2004 Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? Inflamm. Bowel Dis. 10: 491-495. *
Alves C, Vieira N, Toralles MB, Lyra A 2006 Human histocompatibility system association with gastrointestinal diseases. Acta Gastroenterol. Latinoam. 36: 86-93.
Alzoghaibi MA, Walsh SW, Willey A, Fowler Iii AA, Graham MF 2003 Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin. Nutr. 22: 529-535. *
Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA 3rd, Graham MF 2004 Linoleic acid induces interleukin-8 production by Crohn's human intestinal smooth muscle cells via arachidonic acid metabolites. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G528-G537. *
Amarapurkar DN, Patel ND, Amarapurkar AD, Agal S, Baigal R, Gupte P 2004 Tissue polymerase chain reaction in diagnosis of intestinal tuberculosis and Crohn's disease. J. Assoc. Physicians India 52: 863-867.
Amarapurkar DN, Patel ND, Rane PS 2008 Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J. Gastroenterol. 14: 741-746. *
Amati L, Caradonna L, Jirillo E, Caccavo D 1999 Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital. J. Gastroenterol. Hepatol. 31: 313-325.
Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, Pellegrino NM, Jirillo E, Caccavo D 2003 Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr. Pharm. Design 9: 1937-1945.
Amati L, Passeri ME, Selicato F, Mastronardi ML, Penna A, Jirillo E, Covelli V 2006 New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 28: 665-681.
Ambrosini R, Barchiesi A, Di Mizio V, Di Terlizzi M, Leo L, Filippone A, Canalis L, Fossaceca R, Carriero A 2007 Inflammatory chronic disease of the colon: how to image. Eur. J. Radiol. 61: 442-448.
Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K 2006 Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J. Gastroenterol. 41: 444-449. *
Ament ME, Berquist W, Vargas J 1988 Advances in ulcerative colitis. Pediatrician 15: 45-57.
American Gastroenterological Association Clinical Practice Committee 2003 American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 125: 1503-1507. *
Amin J, Wong M 1999 Measles-Mumps-Rubella immunisation, autism and inflammatory bowel disease: update. CDI: Current Issues in Immunisation 23: 222 [http://www.cda.gov.au/pubs/cdi/1999/cdi2308/pdf/cdi2308e.pdf]. *
Amitai MM, Arazi-Kleinman T, Avidan B, Apter S, Konen E, Biegon A, Hertz M 2007 Fat halo sign in the bowel wall of patients with Crohn's disease. Clin. Radiol. 62: 994-997.
Amitai MM, Arazi-Kleinman T, Hertz M, Apter S, Portnoy O, Guranda L, Chowers Y, Avidan B 2008 Multislice CT compared to small bowel follow-through in the evaluation of patients with Crohn disease. Clin. Imaging 32: 355-361.
Ammon HP 2006 Boswellic acids in chronic inflammatory diseases. Planta Med. 72: 1100-1116.
Amonkar SJ, Hughes T, Browell DA 2007 Crohn's disease discovered by an obstructing chick pea. Br. J. Hosp. Med. (Lond.) 68: 445.
Amoudruz P, Holmlund U, Schollin J, Sverremark-Ekstrom E, Montgomery SM 2008 Maternal country of birth and previous pregnancies are associated with breast milk characteristics. Pediatr. Allergy Immunol. May 15 [Epub ahead of print].
Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, Israel D, Mack D, Ghadirian P, Deslandres C, Chotard V, Budai B, Law L, Levy E, Seidman EG 2007 Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am. J. Gastroenterol. 102: 2016-2025. *
Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, Grimard G, Israel D, Mack D, Seidman EG 2006 Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am. J. Gastroenterol. 101: 1005-1011. *
Amre DK, Lu SE, Costea F, Seidman EG 2006 Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am. J. Gastroenterol. 101: 645-652. *
Amre DK, Mack D, Israel D, Morgan K, Lambrette P, Law L, Grimard G, Deslandres C, Krupoves A, Bucionis V, Costea I, Bissonauth V, Feguery H, D'Souza S, Levy E, Seidman EG 2008 Association between genetic variants in the IL-23R gene and early-onset Crohn's disease: results from a case-control and family-based study among Canadian children. Am. J. Gastroenterol. 103: 615-620. *
Amre DK, Mack DR, Israel D, Morgan K, Krupoves A, Costea I, Lambrette P, Grimard G, Deslandres C, Levy E, Seidman EG 2008 Investigation of associations between the pregnane X receptor gene (NR1I2) and Crohn's disease in Canadian children using a gene-wide haplotype-based approach. Inflamm. Bowel Dis. 14: 1214-1218. *
Amre DK, Seidman EG 2003 DNA variants in cytokine and NOD2 genes, exposures to infections and risk for Crohn's disease. Paediatr. Perinat. Epidemiol. 17: 302-312.
Amu J, Phadnis S, Sanusi A 2007 Bartholin's gland carcinoma from Crohn's disease. J. Obstet. Gynaecol. 27: 98-99.
Amundsen SS, Vatn M; the IBSEN study group; Wijmenga C, Sollid LM, Lie BA 2006 Association analysis of MYO9B gene polymorphisms and inflammatory bowel disease in a Norwegian cohort. Tissue Antigens 68: 249-252. *
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB 2007 Bioavailability of curcumin: problems and promises. Mol. Pharm. 4: 807-818. *
Anand V, Russell AS, Tsuyuki R, Fedorak R 2008 Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can. J. Gastroenterol. 22: 33-36.
Anandasabapathy S 2008 Endoscopic imaging: emerging optical techniques for the detection of colorectal neoplasia. Curr. Opin. Gastroenterol. 24: 64-69.
Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG 2007 Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 682-688.
Ananthakrishnan AN, McGinley EL, Binion DG 2008 Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57: 205-210.
Ananthakrishnan AN, McGinley EL, Binion DG 2008 Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am. J. Gastroenterol. Aug 5 [Epub ahead of print]. *
Ananthakrishnan AN, McGinley EL, Binion DG 2008 Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm. Bowel Dis. Jul 30 [Epub ahead of print].
Ananthakrishnan AN, Weber LR, Knox JF, Skaros S, Emmons J, Lundeen S, Issa M, Otterson MF, Binion DG 2008 Permanent work disability in Crohn's disease. Am. J. Gastroenterol. 103: 154-161. *
And ABERMAD 2004 Crohn's disease in the over-60 age group: a population based study. Eur. J. Gastroenterol. Hepatol. 16: 657-664.
Andersen J, Kehlet H 2005 Fast track open ileo-colic resections for Crohn's disease. Colorectal Dis. 7: 394-397. *
Andersen K, Vogt C, Blondin D, Beck A, Heinen W, Aurich V, Haussinger D, Modder U, Cohnen M 2006 Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur. J. Radiol. 58: 140-146.
Anderson DW 2001 Cytokines as drug targets. IDrugs 4: 375-377.
Andersson P, Olaison G, Hallbook O, Boeryd B, Sjodahl R 2003 Increased anal resting pressure and rectal sensitivity in Crohn's disease. Dis. Colon Rectum 46: 1685-1689.
Andersson RE, Olaison G, Tysk C, Ekbom A 2003 Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 124: 40-46. *
Andersson UG, Tracey KJ 2004 HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J. Intern. Med. 255: 318-319. *
Ando T, Nobata K, Watanabe O, Ina K, Kusugami K, Maeda O, Ishiguro K, Ohmiya N, Niwa Y, Goto H 2007 Abnormalities in the upper gastrointestinal tract in inflammatory bowel disease. Inflammopharmacology Apr 28 [Epub ahead of print].
Ando T, Watanabe O, Nobata K, Ishiguro K, Maeda O, Ishikawa D, Hasegawa M, Kondo S, Kato T, Ohmiya N, Niwa Y, Goto H 2008 Immunological status of the stomach in inflammatory bowel disease - comparison between ulcerative colitis and Crohn's disease. Digestion 77: 145-149.
Ando Y, Matsushita M, Kawamata S, Shimatani M, Fujii T, Okazaki K 2008 Infliximab for severe gastrointestinal bleeding in Crohn's disease. Inflamm. Bowel Dis. Jul 30 [Epub ahead of print].
Andoh A, Bamba T 2002 Treatment of Crohn's disease by anti-cytokine monoclonal antibodies. Nippon Rinsho 60: 117-122.
Andoh A, Deguchi Y, Inatomi O, Yagi Y, Bamba S, Tsujikawa T, Fujiyama Y 2006 Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol. Rep. 16: 103-107. *
Andoh A, Endo Y, Kushima R, Hata K, Tsujikawa T, Sasaki M, Mekata E, Tani T, Fujiyama Y 2006 A case of Crohn's disease involving the gallbladder. World J. Gastroenterol. 12: 977-978. *
Andoh A, Fujino S, Hirai Y, Fujiyama Y 2004 Epimorphin expression in human colonic myofibroblasts. Int. J. Mol. Med. 13: 57-61.
Andoh A, Fujino S, Okuno T, Fujiyama Y, Bamba T 2002 Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J. Gastroenterol. 37 Suppl. 14: 33-37.
Andoh A, Fujiyama Y 2006 Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J. Gastroenterol. 12: 4452-4460. *
Andoh A, Hirashima M, Maeda H, Hata K, Inatomi O, Tsujikawa T, Sasaki M, Takahashi K, Fujiyama Y 2005 Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition 21: 574-579. *
Andoh A, Saotome T, Sato H, Tsujikawa T, Araki Y, Fujiyama Y, Bamba T 2001 Epithelial expression of caveolin-2, but not caveolin-1, is enhanced in the inflamed mucosa of patients with ulcerative colitis. Inflamm. Bowel Dis. 7: 210-214. *
Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y 2008 Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. Jul 23 [Epub ahead of print].
Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, Yoshida T, Fujiyama Y 2005 Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am. J. Gastroenterol. 100: 2042-2048. *
Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y 2008 Mucosal cytokine network in inflammatory bowel disease. World J. Gastroenterol. 14: 5154-5161. *
Andoh A, Yoshida T, Yagi Y, Bamba S, Hata K, Tsujikawa T, Kitoh K, Sasaki M, Fujiyama Y 2006 Increased aggregation response of platelets in patients with inflammatory bowel disease. J. Gastroenterol. 41: 47-54. *
Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y 2005 Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984. *
Andrabi SI, Ahmad J, Rathore MA, El-Hakeem AA 2007 Gallbladder perforation in a patient on steroid therapy. N. Z. Med. J. 120: U2686.
Andre MF, Aumaitre O, Piette JC, Grateau G, Cardoso MC, Ouchchane L, Kemeny JL, Dastugue B, Delpech M, Creveaux I 2008 Analysis of the NOD2/CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease. Dig. Dis. Sci. 53: 490-499. *
Andre MF, Kemeny JL, Aumaitre O 2007 Aseptic abscesses: entity already described in Crohn's disease: comment on the case report by Holstein et al. J. Gastroenterol. Hepatol. 22: 765. *
Andreakos E 2004 Common and uncommon features of rheumatoid arthritis and chronic obstructive pulmonary disease: clues to a future therapy. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 85-92.
Andreakos E, Foxwell B, Feldmann M 2004 Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol. Rev. 202: 250-265. *
Andreani ML, Frasca G, Brusco G, Borgnino L, Biagi F, Gasbarrini G, Corazza GR 1996 Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: diagnostic tool or research procedure?. Ann. Ital. Med. Int. 11: 254-257.
Andreani SM, Dang HH, Edwards DP, Baig MK, Khan M, Payne JG 2006 Ovarian Crohn's disease: contiguous or metastatic? Inflamm. Bowel Dis. 12: 1091-1092. *
Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP 2007 Rectovaginal fistula in Crohn's disease. Dis. Colon Rectum 50: 2215-2222. *
Andreassen H, Rix M, Brot C, Eskildsen P 1998 Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand. J. Gastroenterol. 33: 1087-1093. *
Andreassen H, Rungby J, Dahlerup JF, Mosekilde L 1997 Inflammatory bowel disease and osteoporosis. Scand. J. Gastroenterol. 32: 1247-1255.
Andres PG, Friedman LS 1999 Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28: 255-281, vii.
Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach S, Kollinger M, Scholmerich J, Gross V 1997 Imbalance of the interleukin 1 system in colonic mucosa - association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2. Gut 41: 651-657. *
Andus T, Gross V 2000 Etiology and pathophysiology of inflammatory bowel disease - environmental factors. Hepatogastroenterology 47: 29-43.
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group 2003 Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig. Dis. Sci. 48: 373-378. *
Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH 2003 Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment. Pharmacol. Ther. 17: 409-414. *
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B 2003 Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436.
Ang TL, Fock KM, Ng TM, Teo EK, Tan YL 2003 Clinical utility, safety and tolerability of capsule endoscopy in urban Southeast Asian population. World J. Gastroenterol. 9: 2313-2316. *
Angelberger S, Fink KG, Schima W, Szlauer R, Vogelsang H, Reinisch W, Gangl A, Novacek G 2007 Complications in Crohn's disease: right-sided ureteric stenosis and hydronephrosis. Inflamm. Bowel Dis. 13: 1056-1057. *
Angelberger S, Reinisch W, Dejaco C, Miehsler W, Waldhoer T, Wehkamp J, Lichtenberger C, Schaeffeler E, Vogelsang H, Schwab M, Teml A 2008 NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am. J. Gastroenterol. 103: 1197-1202. *
Angeloni G, Latteri M, Manna R, Rumi C, Gasbarrini G, Navarra P 2004 Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients. Eur. J. Clin. Pharmacol. 60: 161-164. *
Angelucci E, Cocco A, Viscido A, Caprilli R 2008 Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm. Bowel Dis. 14: 435-436.
Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R 2007 Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm. Bowel Dis. 13: 1059-1061. *
Angriman I, Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF, Plebani M 2007 Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin. Chim. Acta 381: 63-68. *
Angriman I, Scarpa M, Ruffolo C, Pomerri F, Filosa T, Polese L, Pagano D, Norberto L, D'Amico DF 2008 Double contrast small-bowel radiography in the preoperative assessment of Crohn's disease: is it still useful? Surg. Today 38: 700-704.
Angulo P, Lindor KD 1999 Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570. *
Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF 2001 Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am. J. Gastroenterol. 96: 2407-2412. *
Annese V, Andreoli A, Astegiano M, Campieri M, Caprilli R, Cucchiara S, D'Inca R, Giaccari S, Iaquinto G, Lombardi G, Napolitano G, Pera A, Riegler G, Valpiani D, Andriulli A; Italian Study Group for the Disease of Colon and Rectum 2001 Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am. J. Gastroenterol. 96: 2939-2945. *
Annese V, Latiano A, Andriulli A 2003 Genetics of inflammatory bowel disease: the beginning of the end or the end of the beginning? Dig. Liver Dis. 35: 442-449.
Annese V, Latiano A, Bovio P, Forabosco P, Piepoli A, Lombardi G, Andreoli A, Astegiano M, Gionchetti P, Riegler G, Sturniolo GC, Clementi M, Rappaport E, Fortina P, Devoto M, Gasparini P, Andriulli A 1999 Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus - a GISC study. Eur. J. Hum. Genet. 7: 567-573. *
Annese V, Latiano A, Palmieri O, Lombardi G, Andriulli A; Italian Group of Inflammatory Bowel Disease 2006 NOD2/CARD15 in healthy relatives of IBD patients. Eur. Rev. Med. Pharmacol. Sci. 10: 33-36.
Annese V, Latiano A, Rossi L, Bossa F, Damonte G, Dallapiccola B, Serafini S, Pierige F, Andriulli A, Magnani M 2006 The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 27-31.
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M 2005 Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study. Am. J. Gastroenterol. 100: 1370-1375. *
Annese V, Lombardi G, Perri F, D'Inca R, Ardizzone S, Riegler G, Giaccari S, Vecchi M, Castiglione F, Gionchetti P, Cocchiara E, Vigneri S, Latiano A, Palmieri O, Andriulli A 2005 Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. Am. J. Gastroenterol. 100: 84-92. *
Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, D'Inca R, Gionchetti P, Papi C, Riegler G, Vecchi M, Andriulli A; Italian Group for Inflammatory Bowel Disease 2004 Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. Dig. Liver Dis. 36: 121-124.
Annese V, Piepoli A, Andriulli A, Latiano A, Napolitano G, Li HH, Forabosco P, Devoto M 2002 Association of Crohn's disease and ulcerative colitis with haplotypes of the MLH1 gene in Italian inflammatory bowel disease patients. J. Med. Genet. 39: 332-334. *
Annese V, Piepoli A, Andriulli A, Napolitano G, Bisceglia L, Zelante L, Gasparini P 1998 Polymorphism of motilin gene in patients with Crohn's disease. Dig. Dis. Sci. 43: 715-719. *
Annese V, Piepoli A, Latiano A, Lombardi G, Napolitano G, Caruso N, Cocchiara E, Accadia L, Perri F, Andriulli A 2005 HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum 48: 57-64.
Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A 2004 Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol. Ther. 20: 1143-1152. *
Annibale B, Capurso G, Baccini F, Lahner E, D'Ambra G, Di Giulio E, Delle Fave G 2003 Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Dig. Liver Dis. 35: 784-787.
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fil� L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S 2007 Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861. *
Ansaldo GL, Varaldo E, Assalino M, Borgonovo G 2004 Artificial nutrition in inflammatory bowel disease. Ann. Ital. Chir. 75: 629-634.
Ansari A, Aslam Z, DE Sica A, Smith M, Gilshenan K, Fairbanks L, Marinaki A, Sanderson J, Duley J 2008 The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment. Pharmacol. Ther. 28: 749-757. *
Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J 2008 Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. Jun 26 [Epub ahead of print]. *
Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J 2008 Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405.
Ansari N, Abdulla J, Zayyani N, Brahmi U, Taha S, Abdel Satir A 2006 Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? J. Clin. Pathol. 59: 1066-1072. *
Anthony A, Dhillon AP, Pounder RE, Wakefield AJ 1999 The colonic mesenteric margin is most susceptible to injury in an experimental model of colonic ulceration. Aliment. Pharmacol. Ther. 13: 531-535. *
Anthony A, Dhillon AP, Pounder RE, Wakefield AJ 1997 Ulceration of the ileum in Crohn's disease: correlation with vascular anatomy. J. Clin. Pathol. 50: 1013-1017. *
Anthony A, Pounder RE, Dhillon AP, Wakefield AJ 2000 Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment. Pharmacol. Ther. 14: 241-245. *
Antoniu SA 2006 Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin. Investig. Drugs 15: 181-184.
Anumakonda V, Hayee B, Chung-Faye G 2007 Remission and relapse of Crohn's disease following autologous haematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Gut 56: 1325. *
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, de Bruin PA, Mieremet-Ooms MA, van der Zon JM, van Tol EA, Lamers CB 1989 In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon. J. Clin. Lab. Immunol. 29: 119-124.
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, Mieremet-Ooms MA, van der Zon JM, de Bruin PA, Lamers CB 1988 Natural, lectin- and phorbol ester-induced cellular cytotoxicity in Crohn's disease and ulcerative colitis. J. Clin. Lab. Immunol. 27: 109-113.
APDW2004 Chinese IBD Working Group 2006 Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003. J. Gastroenterol. Hepatol. 21: 1009-1015. *
Apgar JT 1991 Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin. Dermatol. 10: 138-147.
Apostolaki M, Manoloukos M, Roulis M, Wurbel MA, Muller W, Papadakis KA, Kontoyiannis DL, Malissen B, Kollias G 2008 Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 134: 2025-2035. *
Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP 2008 Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J. Gastrointest. Surg. Aug 12 [Epub ahead of print]. *
Appleyard CB, Hernandez G, Rios-Bedoya CF 2004 Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm. Bowel Dis. 10: 106-111. *
Aquilina P, Savage NW, Lynham A 2003 Crohn's disease with oral presenting signs masquerading as chronic osteomyelitis. Aust. Dent. J. 48: 134-137.
Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H 1998 Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig. Dis. Sci. 43: 2071-2079. *
Arai T, Esaki Y, Sawabe M, Honma N, Nakamura KI, Takubo K 2004 Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod. Pathol. 17: 172-179. *
Araki Y, Sugihara H, Hattori T 2006 The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice. Int. J. Mol. Med. 17: 331-334. *
Aranda R, Horgan K 1998 Immunosuppressive drugs in the treatment of inflammatory bowel disease. Semin. Gastrointest. Dis. 9: 2-9.
Aratari A, Caprilli R 2006 Seasonality in onset of symptoms in Crohn's disease. Dig. Liver Dis. 38: 356.
Aratari A, Papi C, Galletti B, Angelucci E, Viscido A, D'Ovidio V, Ciaco A, Abdullahi M, Caprilli R 2006 Seasonal variations in onset of symptoms in Crohn's disease. Dig. Liver Dis. 38: 319-323.
Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R 2007 Early versus late surgery for ileo-caecal Crohn's disease. Aliment. Pharmacol. Ther. 26: 1303-1312. *
Ardizzone S 2003 Ulcerative colitis. Orphanet encyclopedia [http://www.orpha.net/data/patho/GB/uk-UC.pdf]. *
Ardizzone S, Bianchi Porro G 2005 Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286.
Ardizzone S, Bianchi Porro G 2007 Perianal Crohn's disease: overview. Dig. Liver Dis. 39: 957-958.
Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G 2000 Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J. Intern. Med. 247: 63-70. *
Ardizzone S, Bollani S, Manzionna G, Colombo E, Maconi G, Imbesi V, Bianchi Porro G 2003 Efficacy of medical therapy in preventing the post-surgical recurrence in Crohn's disease. Ann. Ital. Chir. 74: 621-625.
Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G 2003 Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig. Liver Dis. 35: 619-627.
Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone MC, Bianchi Porro G 2002 Infliximab in treatment of Crohn's disease: the Milan experience. Dig. Liver Dis. 34: 411-418.
Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, Penati C, Tenchini ML, Bianchi Porro G 2007 Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 13: 516-523. *
Ardizzone S, Maconi G, Cassinotti A, Massari A, Bianchi Porro G 2007 Imaging of perianal Crohn's disease. Dig. Liver Dis. 39: 970-978.
Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Porro GB 2004 Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm. Bowel Dis. 10: 91-96. *
Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G 2004 Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730-740. *
Ardizzone S, Porro GB 2005 Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission? Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 348-349. *
Ardizzone S, Porro GB 2008 Is it possible to modify the clinical course of Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 428-429.
Ardizzone S, Puttini PS, Cassinotti A, Porro GB 2008 Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40 Suppl. 2: S253-S259.
Arend SM, Breedveld FC, van Dissel JT 2003 TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. 61: 111-119. *
Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT 2007 A patient with de novo tuberculosis during anti-tumor necrosis factor- alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin. Infect. Dis. 45: 1470-1475. *
Arents NL, Thijs JC, Van Zwet AA, Kleibeuker JH 2004 Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur. J. Gastroenterol. Hepatol. 16: 779-783.
Arfaoui D, Elloumi H, Debbebi W, Bel Hadj Ali N, Ajmi S 2007 Psychological disorder associated to inflammatory bowel disease. Tunis. Med. 85: 189-191.
Arfaoui D, Elloumi H, Salah A, Ajmi S 2005 Predictive factors of recurrence in Crohn's disease. Tunis. Med. 83: 83-86.
Argov S, Sahu RK, Bernshtain E, Salman A, Shohat G, Zelig U, Mordechai S 2004 Inflamatory bowel diseases as an intermediate stage between normal and cancer: a FTIR-microspectroscopy approach. Biopolymers 75: 384-392. *
Arguelles Arias F, Arguelles Martin F, Caunedo Alvarez A, Rodriguez-Tellez M, Herrerias Gutierrez JM 2003 Utility of capsule endoscopy in pediatric gastroenterology. An. Pediatr. (Barc.) 59: 586-589.
Arguelles-Arias F, Arguelles Martin F, Caunedo Alvarez A, Sanchez Yague A, Romero Vazquez J, Garcia Montes MJ, Rodriguez-Tellez M, Pellicer Bautista FJ, Herrerias Gutierrez JM 2007 Is capsule endoscopy useful in children with chronic abdominal pain? An. Pediatr. (Barc.) 67: 385-389.
Arguelles-Arias F, Caunedo A, Romero J, Sanchez A, Rodriguez-Tellez M, Pellicer FJ, Arguelles-Martin F, Herrerias JM 2004 The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease. Endoscopy 36: 869-873.
Arihiro S, Ohtani H, Suzuki M, Murata M, Ejima C, Oki M, Kinouchi Y, Fukushima K, Sasaki I, Nakamura S, Matsumoto T, Torii A, Toda G, Nagura H 2002 Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol. Int. 52: 367-374. *
Arin Letamendia A, Borda Celaya F, Burusco Paternain MJ, Prieto Martinez C, Martinez Echeverria A, Elizalde Apestegui I, Laiglesia Izquierdo M, Macias Mendizabal E, Tamburri Moso P, Sanchez Valverde F 2008 High incidence rates of inflammatory bowel disease in Navarra (Spain). Results of a prospective, population-based study. Gastroenterol. Hepatol. 31: 111-116.
Arluk GM, Pickhardt PJ 2004 Images in clinical medicine. Inflammatory pseudopolyposis in Crohn's disease. N. Engl. J. Med. 350: 923. *
Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G 2008 Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205: 331-337. *
Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, Satsangi J 2004 Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 127: 1051-1057. *
Armuzzi A, Ahmad T, Ling KL, De Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP 2003 Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52: 1133-1139. *
Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A 2008 Infliximab in Crohn's disease: early and long-term treatment. Dig. Liver Dis. 40 Suppl. 2: S271-S279.
Arnold GL, Beaves MR, Pryjdun VO, Mook WJ 2002 Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8: 10-15. *
Arnott ID, Drummond HE, Ghosh S 2001 Frequency of continuing mucosal inflammation in clinically inactive Crohn's disease. Scott. Med. J. 46: 136-139.
Arnott ID, Ho GT, Nimmo ER, Satsangi J, Franchimont D, Vermeire S, Deviere J, Rutgeerts PJ 2005 Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe (Author's reply). Gut 54: 308-309. *
Arnott ID, Kingstone K, Ghosh S 2000 Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand. J. Gastroenterol. 35: 1163-1169. *
Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J 2004 Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99: 2376-2384. *
Arnott ID, McDonald D, Williams A, Ghosh S 2001 Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment. Pharmacol. Ther. 15: 1639-1646. *
Arnott ID, McNeill G, Satsangi J 2003 An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17: 1451-1457. *
Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, Morecroft J, Anderson N, Kelleher D, O'Sullivan M, McManus R, Satsangi J 2004 NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 5: 417-425. *
Arnott ID, Satsangi J 2003 Crohn's disease or Crohn's diseases? Gut 52: 460-461. *
Arnott ID, Shand A, Ghosh S 2000 Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. Am. J. Gastroenterol. 95: 3326-3327. *
Arnott ID, Watts D, Satsangi J 2003 Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47: 1-10. *
Aronoff JS, Korelitz BI, Sohn N, Ky A, Rajapakse R, Weinstein MA, Cohen FS 2000 Anorectal Crohn's disease: surgical and medical management. BioDrugs 13: 95-105.
Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz RP 2008 Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 15: 46-53.
Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martinez C 2006 Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann. N. Y. Acad. Sci. 1070: 129-134. *
Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martinez C 2008 VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29: 948-956. *
Arseneau KO, Stukenborg GJ, Connors AF Jr, Cominelli F 2001 The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm. Bowel Dis. 7: 106-112. *
Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F 2007 Innate and adaptive immune responses related to IBD pathogenesis. Curr. Gastroenterol. Rep. 9: 508-512.
Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, Wright TB, Nasser MS, de Villiers WJ, Kaetzel CS 2008 Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol. 1: 399-411.
Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A 2002 Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids 37: 935-940.
Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A 2003 Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 50: 952-956.
Asakura H 2002 Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody. Nippon Rinsho 60: 531-538.
Asakura H, Sugimura K 1999 Present states of development in new drugs and treatment of inflammatory bowel disease. Nippon Rinsho 57: 2490-2495.
Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T 2001 Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J. Gastroenterol. Hepatol. 16: 763-769. *
Aschoff AJ 2006 MDCT of the abdomen. Eur. Radiol. 16 Suppl. 7: M54-M57.
Asheim P, Uggen PE, Aasarod K, Aadahl P 2006 Intraperitoneal fluid therapy: an alternative to intravenous treatment in a patient with limited vascular access. Anaesthesia 61: 502-504. *
Ashley MJ 1997 Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Can. J. Gastroenterol. 11: 345-352.
Ashok D, Kiely P 2007 Bowel associated dermatosis - arthritis syndrome: a case report. J. Med. Case Reports 1: 81. *
Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S 2008 Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. Jul 10 [Epub ahead of print].
Ashorn S, Raukola H, Valineva T, Ashorn M, Wei B, Braun J, Rantala I, Kaukinen K, Luukkaala T, Collin P, M�ki M, Iltanen S 2008 Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J. Clin. Immunol. May 22 [Epub ahead of print]. *
Ashwood P, Anthony A, Torrente F, Wakefield AJ 2004 Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J. Clin. Immunol. 24: 664-673. *
Ashwood P, Wakefield AJ 2006 Immune activation of peripheral blood and mucosal CD3(+) lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J. Neuroimmunol. 173: 126-134.
Asimakopoulos G 2004 Pregnancy and inflammatory bowel disease. Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 46-50.
Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, Ekbom A 2005 Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54: 617-622. *
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A 2001 Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357: 262-266. *
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A 2001 Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120: 1356-1362. *
Asma SD, Soumaya Y, Kahena J, Raouf DM, Nejib D 2006 Perianal Crohn disease. Dermatol. Online J. 12: 18.
Aspberg S, Dahlquist G, Kahan T, Kallen B 2006 Fetal and perinatal risk factors for inflammatory bowel disease. Acta Paediatr. 95: 1001-1004. *
Aspinall RJ 2004 Are adherent Escherichia coli in Crohn's disease and colon cancer truly pathogenic? Gastroenterology 127: 1649-1650. *
Asplund S, Gramlich T, Fazio V, Petras R 2002 Histologic changes in defunctioned rectums in patients with inflammatory bowel disease: a clinicopathologic study of 82 patients with long-term follow-up. Dis. Colon Rectum 45: 1206-1213.
Asquith DL, McInnes IB 2007 Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251.
Asquith P, Thompson RA, Cooke WT 1975 Oral manifestations of Crohn's disease. Gut 16: 1249-1254. *
Assche GV, Rutgeerts P 2004 Medical management of postoperative recurrence in Crohn's disease. Gastroenterol. Clin. North Am. 33: 347-360.
Astegiano M, Bresso F, Demarchi B, Sapone N, Novero D, Palestro G, Resegotti A, Pellicano R, Rizzetto M 2005 Association between Crohn's disease and Conn's syndrome. A report of two cases. Panminerva Med. 47: 61-64.
Astegiano M, Cammarota T, Bresso F, Sapone N, Demarchi B, Bertolusso L, Sarno A, Bruno M, Pellicano R, Rizzetto M 2001 Abdominal pain and bowel dysfunction: diagnostic flow-chart could be semplified? Minerva Gastroenterol. Dietol. 47: 53-60.
Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M 2007 Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study. Biomed. Pharmacother. 61: 370-376.
Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F 2006 Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand. J. Gastroenterol. 41: 1064-1072. *
Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K 2008 Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig. Dis. Sci. 53: 2215-2221. *
Athanasiadis S, Yazigi R, Kohler A, Helmes C 2007 Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques. Int. J. Colorectal Dis. 22: 1051-1060. *
Atienza P 2007 Refractory perineal fistulas in Crohn's disease. Gastroenterol. Clin. Biol. 31: 404-411.
Atreya I, Atreya R, Neurath MF 2008 NF-kappaB in inflammatory bowel disease. J. Intern. Med. 263: 591-596. *
Atreya R, Atreya I, Neurath MF 2006 Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1072: 98-113. *
Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF 2000 Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588. *
Atreya R, Neurath MF 2008 Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr. Drug Targets 9: 369-374.
Atreya R, Neurath MF 2005 Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 28: 187-196.
Attar A, Bon C, Sebbagh V, Bejou B, Benamouzig R 2007 Endoscopic argon plasma coagulation for the treatment of hemorrhagic pseudopolyps in colonic Crohn's disease. Endoscopy 39: E249.
Attard TM, Horton KM, DeVito K, Darbari A, Oliva-Hemker M, Thompson R, Cuffari C 2004 Pediatric jejunoileitis: a severe Crohn's disease phenotype that requires intensive nutritional management. Inflamm. Bowel Dis. 10: 357-360. *
Attvall E, Frigyesi A, Sternby B 2006 What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int. J. Colorectal Dis. 21: 705-710. *
Attwood SE, Lamb CA 2008 Eosinophilic oesophagitis and other non-reflux inflammatory conditions of the oesophagus: Diagnostic imaging and management. Best Pract. Res. Clin. Gastroenterol. 22: 639-660.
Atug O, Hamzaoglu H, Tahan V, Alican I, Kurtkaya O, Elbuken E, Ozdogan O, Tozun N 2008 Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. Dig. Dis. Sci. 53: 481-485. *
Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, DE Portu S, Carrabba M, Bianchi Porro G 2005 Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment. Pharmacol. Ther. 22: 453-461. *
Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P 2007 Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev. 6: 529-536.
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F 2005 Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4: 144-152.
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P 2005 Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 1051: 559-569.
Audrain MA, Gourbil A, Muller JY, Esnault LM 1996 Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. J. Autoimmun. 9: 569-574.
Auer IO 1983 Immunologic aspects of chronic inflammatory intestinal diseases. Klin. Padiatr. 195: 337-341.
Auer IO, Buschmann C, Ziemer E 1978 Immune status in Crohn's disease. 2. Originally unimpaired primary cell mediated immunity in vitro. Gut 19: 618-626. *
Auer IO, Gotz S, Ziemer E, Malchow H, Ehms H 1979 Immune status in Crohn's disease. 3. Peripheral blood B lymphocytes, enumerated by means of F(ab)2-antibody fragments, Null and T lymphocytes. Gut 20: 261-268. *
Auer IO, Roder A, Wensinck F, van de Merwe JP, Schmidt H 1983 Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand. J. Gastroenterol. 18: 217-223.
Auer IO, Ziemer E, Sommer H 1980 Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood. Clin. Exp. Immunol. 42: 41-49. *
Auernhammer CJ, Zitzmann K, Schnitzler F, Seiderer J, Lohse P, Vlotides G, Engelhardt D, Sackmann M, Goke B, Ochsenkuhn T 2005 Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease. World J. Gastroenterol. 11: 1196-1199. *
Augoustides JG, Pochettino A, Pyeritz RE 2007 Successful surgical management of acute type A aortic dissection associated with Crohn disease. J. Thorac. Cardiovasc. Surg. 134: 1048-1049.
Auslander JN, Lieberman DA, Sonnenberg A 2005 Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 100: 2233-2238. *
Austin GL, Shaheen NJ, Sandler RS 2006 Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am. J. Gastroenterol. 101: 413-416. *
Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F 2006 Pharmacovigilance of vaccines. Arch. Pediatr. 13: 175-180.
Autret-Leca E, Jonville-Bera AP, Beau-Salinas F 2004 Vaccines pharmacovigilance. Rev. Prat. 54: 526-531.
Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir ZI, Wallich R, Otto HF, Meuer SC 1998 In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 153: 121-130. *
Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, Loffler T, Buchler MW, Schmidt J 2005 High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54: 944-949. *
Autschbach F, Funke B, Katzenmeier M, Gassler N 2005 Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver - an immunohistochemical analysis with new monoclonal antibodies from the 8th international workshop and conference on human leucocyte differentiation antigens. Cell. Immunol. 236: 110-114. *
Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U, Zuna I, Schulz P, Weckauf H, Berger I, Otto HF, Meuer SC 2002 Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 441: 500-513. *
Auvin S, Molinie F, Gower-Rousseau C, Brazier F, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, Cortot A, Turck D 2005 Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in Northern France (1988-1999). J. Pediatr. Gastroenterol. Nutr. 41: 49-55. *
Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, Bar-Meir S, Chowers Y 2005 Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 72: 248-253.
Avital S, Hermon H, Greenberg R, Karin E, Skornick Y 2006 Learning curve in laparoscopic colorectal surgery: our first 100 patients. Isr. Med. Assoc. J. 8: 683-686.
Awad J, Farah R, Reshef R, Cohen H, Horn I 2006 Pyloric stenosis as a presenting symptom of Crohn's disease. J. Gastrointestin. Liver Dis. 15: 175-177. *
Awotesu O, Missotten T, Pitcher MC, Lynn WA, Lightman S 2004 Uveitis in a patient receiving rifabutin for Crohn's disease. J. R. Soc. Med. 97: 440-441.
Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H 2008 Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47: 142-144.
Aylett P 2006 Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. IDrugs 9: 452-454.
Ba'ath ME, Mahmalat M, Smith NP, Dalzell M, Casson DH, Lamont GL, Baillie CT 2007 Surgical management of inflammatory bowel disease. Arch. Dis. Child. 92: 312-316.
Babb RR 1988 The use of metronidazole (Flagyl) in Crohn's disease. J. Clin. Gastroenterol. 10: 479-481.
Babu TG, Boctor D, Davey A, Bond MC, Jacobson K 2004 Cytomegalovirus-associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J. Pediatr. Gastroenterol. Nutr. 39: 418-421. *
Baburajan B, Parkes M 2003 The genetics of inflammatory bowel disease. Hosp. Med. 64: 599-602.
Babusukumar U, Wang T, McGuire E, Broeckel U, Kugathasan S 2006 Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn's disease. Am. J. Gastroenterol. 101: 1354-1361. *
Babyatsky MW, Rossiter G, Podolsky DK 1996 Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984. *
Baca B, Hamzaoglu I, Karahasanoglu T, Hamzaoglu HO 2007 Laparoscopic treatment of pyogenic liver abscess complicating Crohn's disease: a case report. Turk. J. Gastroenterol. 18: 58-61. *
Bacher S, Schmitz ML 2004 The NF-kappa B pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10: 2827-2837.
Bachmann C, Klibanov AL, Olson TS, Sonnenschein JR, Rivera-Nieves J, Cominelli F, Ley KF, Lindner JR, Pizarro TT 2006 Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology 130: 8-16. *
Bachmann O, Baus S, Hoffmann MW, Manns MP, Gebel M 2005 Incarcerated Spieghel-Hernie mimicking an acute exacerbation of Crohn's disease. Z. Gastroenterol. 43: 1309-1312.
Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Medioni J, Dhote R, Mougeot-Martin M 1998 Acute autoimmune sensorineural hearing loss associated with Crohn's disease. Am. J. Gastroenterol. 93: 2565-2567. *
Bachvarov DR, Landry M, Houle S, Pare P, Marceau F 1998 Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. Gastroenterology 115: 1045-1048. *
Bachwich DR, Lichtenstein GR, Traber PG 1994 Cancer in inflammatory bowel disease. Med. Clin. North Am. 78: 1399-1412.
Bacon PA 1991 Vasculitic syndromes associated with other rheumatic conditions and unclassified systemic vasculitis. Curr. Opin. Rheumatol. 3: 56-61.
Badina L, Taddio A, Ventura A 2008 Early combined immunosuppression in Crohn's disease. Lancet 371: 1995.
Baert F, Caprilli R, Angelucci E 2007 Medical therapy for Crohn's disease: top-down or step-up? Dig. Dis. 25: 260-266.
Baert F, De Vos M, Louis E, Vermeire S; Belgian IBD Research Group 2007 Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70: 163-170.
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P 2003 Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608. *
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P 2004 Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59: 304-314.
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ 1999 Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28. *
Baert FJ, Rutgeerts PJ 2000 Medical therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 2: 446-450.
Baert FJ, Rutgeerts PR 1999 Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int. J. Colorectal Dis. 14: 47-51. *
Bagnoli S, P